Jeong Sinyoung, Kim Yong-il, Kang Homan, Kim Gunsung, Cha Myeong Geun, Chang Hyejin, Jung Kyung Oh, Kim Young-Hwa, Jun Bong-Hyun, Hwang Do Won, Lee Yun-Sang, Youn Hyewon, Lee Yoon-Sik, Kang Keon Wook, Lee Dong Soo, Jeong Dae Hong
Department of Chemistry Education, Seoul National University, Seoul 151-744, Republic of Korea.
1] Department of Nuclear Medicine, College of Medicine, Seoul National University, Seoul 110-744, Republic of Korea [2] Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 151-747, Republic of Korea.
Sci Rep. 2015 Mar 30;5:9455. doi: 10.1038/srep09455.
Optical endoscopic imaging, which was recently equipped with bioluminescence, fluorescence, and Raman scattering, allows minimally invasive real-time detection of pathologies on the surface of hollow organs. To characterize pathologic lesions in a multiplexed way, we developed a dual modal fluorescence-Raman endomicroscopic system (FRES), which used fluorescence and surface-enhanced Raman scattering nanoprobes (F-SERS dots). Real-time, in vivo, and multiple target detection of a specific cancer was successful, based on the fast imaging capability of fluorescence signals and the multiplex capability of simultaneously detected SERS signals using an optical fiber bundle for intraoperative endoscopic system. Human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) on the breast cancer xenografts in a mouse orthotopic model were successfully detected in a multiplexed way, illustrating the potential of FRES as a molecular diagnostic instrument that enables real-time tumor characterization of receptors during routine endoscopic procedures.
光学内镜成像技术最近配备了生物发光、荧光和拉曼散射功能,能够对中空器官表面的病变进行微创实时检测。为了以多重方式表征病理病变,我们开发了一种双模态荧光-拉曼内镜系统(FRES),该系统使用荧光和表面增强拉曼散射纳米探针(F-SERS点)。基于荧光信号的快速成像能力以及使用光纤束用于术中内镜系统同时检测SERS信号的多重能力,成功实现了对特定癌症的实时、体内和多靶点检测。在小鼠原位模型中的乳腺癌异种移植瘤上,成功以多重方式检测到了人表皮生长因子受体2(HER2)和表皮生长因子受体(EGFR),这说明了FRES作为一种分子诊断仪器的潜力,它能够在常规内镜检查过程中对受体进行实时肿瘤表征。